To evaluate corneal endothelium cell change after intravitreal Bevacizumab injection

Intravitreal Bevacizumab has been used by retinal specialist in treatment many retinal diseases. Although it not approved by FDA for treatment. In many In vitro studies, its showed saftey in the eyes especially for corneal endothelium cells, that important cells to keep cornea clear. This study use Confoscan-Corneal confocal microsope to evaluate corneal endothelium before and after intravitreal Bevacizumab injection in routine retinal disease at 6 month follow up.

Inclusion Criteria:

• aged between 20 and 80 years old
• can come to regular follow up at 6 month
• signed written consent forms
• not have corneal scar, or glaucoma
• history of treatment with laser or anti-VEGF therapy in 3 month prior to recruit
• high risk in cerebrovascular and cardiovascular diseases
• Pregnancy and breastfeeding
• can undergo confocal microspopy

Exclusion Criteria:

• History of intraocular surgery or ocular trauma during study

Patient in retinalvascular clinic with diagnosis of retinal vein occlusion with macular edema, diabetic macular edema, wet aged related macular degeneration and submacular hemorrhage)treated with intravitreal Bevacizumab